TM4SF18 Inhibitors

Chemical inhibitors of TM4SF18 operate through various mechanisms to ensure the functional inhibition of this protein. Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which can phosphorylate TM4SF18, leading to its functional inhibition by potentially altering its localization and/or interaction with other proteins. On the other hand, Staurosporine, a potent PKC inhibitor, prevents the phosphorylation of TM4SF18 that is necessary for its activity, thereby inhibiting its function. Bisindolylmaleimide I specifically inhibits PKC, which is required for the phosphorylation and activation of TM4SF18, thereby inhibiting its activity. Similarly, Gö 6983, a pan-PKC inhibitor, and Gö 6976, which inhibits classical PKC isoforms, prevent the phosphorylation and subsequent activation of TM4SF18, resulting in its inhibition.

Further down the line of PKC inhibitors, Sotrastaurin selectively inhibits PKC, potentially reducing the phosphorylation-dependent activation of TM4SF18 and leading to its functional inhibition. LY333531 selectively targets PKCβ, which is involved in the phosphorylation of TM4SF18, thereby inhibiting its function. Rottlerin, as a PKCδ inhibitor, leads to reduced phosphorylation and activity of TM4SF18, resulting in its inhibition. Chelerythrine and Ruboxistaurin, both PKC inhibitors, prevent phosphorylation and therefore the activation of TM4SF18, leading to its functional inhibition. Enzastaurin also inhibits PKCβ, playing a role in the regulation of TM4SF18 and leading to decreased phosphorylation and activity. Lastly, Hispidin serves as a PKC inhibitor and, by inhibiting PKC, the necessary phosphorylation of TM4SF18 for its activation is prevented, thus functionally inhibiting the protein.